Specifications tableSubjectClinical BiochemistrySpecific subject areaEndocrinology, Diabetes and Metabolism, Lipid metabolism, Pediatric dataType of dataFigureHow data were acquiredThis retrospective study was conducted by extracting HbA1c and LDL-c data for all zones from the New Brunswick Diabetes Registry, anonymously.Data formatRawAnalyzedParameters for data collectionThe New Brunswick Diabetes Registry identifies diabetes based on the Canadian Chronic Disease Surveillance System (CCDSS) and HbA1c data. The diabetes registry includes patients meeting one of the following criteria: (a) Two Medicare claims within a 2 year period that specify diabetes as the reason for the visit, (b) A hospital admission (from Discharge Abstract Data) with a diagnosis of diabetes, whether or not it was the primary reason for admission, (c) A historical record of at least one HbA1c ≥ 48 mmol/mol (6.5%).Description of data collectionData for pediatric diabetic patients were obtained from the New Brunswick Diabetes Registry from 2008 to 2014.Data source locationFredericton, New Brunswick, CanadaData accessibilityWith the articleRelated research articleWang D, Chen Y, Usefulness of Estimated Average Glucose (eAG) in Glycemic Control and Cardiovascular Risk Reduction, Clin. Biochem. (EPub on June 14, 2020). doi: 10.1016/j.clinbiochem.2020.06.009.

Value of the data {#sec0001a}
=================

Value of the Data•This study provides previously unreported the clinical usefulness of estimated average glucose (eAG) on glycemic control and blood lipid control in *pediatric* diabetic patients.•The data helps clinicians and medical laboratories to decide on whether to implement eAG calculation or not.•On a national and international level, these data can assist as a basis for further studies on diabetic biomarker evaluation and assessment.

1. Data description {#sec0001}
===================

The data contains information on the distributions of HbA1c and LDL-c values ([Fig. 1](#fig0001){ref-type="fig"}), and proportions of diabetic patients achieving therapeutic targets (HbA1c\<53 mmol/mol (7.0%) and LDL-*c*\<2.6 mmol/L) ([Fig. 2](#fig0002){ref-type="fig"}) of pediatric diabetic patients in Zone 1.1 before and after eAG implementation in January 2010. It also contains information on the proportions of diabetic patients achieving therapeutic targets of HbA1c and LDL-c ([Fig. 3](#fig0003){ref-type="fig"}) and overall medians of HbA1c and LDL-c values ([Fig. 4](#fig0004){ref-type="fig"}) in all 8 regional health authority zones of New Brunswick from 2008 to 2014. Furthermore, the distributions of HbA1c (A) and LDL-c (B) values of pediatric diabetic patients in all 8 regional health authority zones of New Brunswick from 2010 to 2014 has been demonstrated in [Fig. 5](#fig0005){ref-type="fig"}. The raw data is also provided as a supplementary file.Fig. 1Distributions of HbA1c and LDL-c values of pediatric diabetic patients in Zone 1.1 before and after eAG implementation. A, HbA1c values; B, LDL-c values.Fig. 1Fig. 2Proportions of pediatric diabetic patients achieving therapeutic targets (HbA1c\<53 mmol/mol (7.0%) and LDL-*c*\<2.6 mmol/L) in Zone 1.1 before and after eAG reporting. A, HbA1c values; B, LDL-c values. Dashed vertical line indicates when Zone 1.1 started to report eAG (January 2010).Fig. 2Fig. 3Proportions of pediatric diabetic patients achieving therapeutic targets of HbA1c and LDL-c in all 8 regional health authority zones of New Brunswick from 2008 to 2014. Of these zones, only Zone 1.1 reported eAG. A, HbA1c values; B, LDL-c values. Dashed vertical line indicates when Zone 1.1 started to report eAG (January 2010).Fig. 3Fig. 4Overall medians of HbA1c and LDL-c values of pediatric diabetic patients in all 8 regional health authority zones of New Brunswick from 2008 to 2014. Of these zones, only Zone 1.1 reported eAG. A, HbA1c values; B, LDL-c values. Dashed vertical line indicates when Zone 1.1 started to report eAG (January 2010).Fig. 4Fig. 5Distributions of HbA1c (A) and LDL-c (B) values of pediatric diabetic patients in 8 regional health authority zones of New Brunswick from 2010 to 2014. The endpoint of upper whisker is the 75th percentile plus 1.5 times IQR, the endpoint of lower whisker is the 25th percentile minus 1.5 times IQR, the line in the box shows the median, the lower and upper edges of box correspond to the first and third quartiles. \*Significant difference (*p* \< 0.05), compared with Zone 1.1.Fig. 5

2. Experimental design, materials and methods {#sec0002}
=============================================

2.1. Subjects {#sec0003}
-------------

This retrospective study was conducted by extracting HbA1c and LDL-c data for all zones from the New Brunswick Diabetes Registry, anonymously, follow the Department of Health privacy and confidentiality policies. There were 8 RHA zones in New Brunswick, among these zones, only Zone 1.1 has been reporting eAG since January 2010. There were total 9417 data points, consisting of 7355 HbA1c values and 2062 LDL-c values from 2008 to 2014. Of these data, 4798 were from male, aged between 3 and 17; and 4619 were from female, aged between 1 and 17. The study was approved by the Research Ethics Board of Horizon Health Network (File\#2015--2087). The Research Ethics Board for Horizon Health Network is organized and operates according to the principles of the Harmonized Tripartite Guidelines: Good Clinical Practice, Tri-Council (Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada) Policy Statement and Division 5 of the Food and Drug Regulations.

2.2. Data analysis {#sec0004}
------------------

One of the main evaluation indicators we took to assess the utility of eAG was the overall proportions of patients achieving therapeutic targets, i.e. HbA1c\<53 mmol/mol (7.0%) and LDL-*c* \<2.6 mmol/L as per American Diabetes Association guidance document [@bib0002]. The distributions of HbA1c and LDL-C levels in Zone 1.1 between 2008 and 2009 as the baseline and 2010--2014 after reporting eAG were analyzed. We also compared the proportions of diabetic patients achieving therapeutic targets in Zone 1.1 before and after the eAG was implemented.

Additionally, to compare whether the glycemic and cholesterol control in diabetic patients in Zone 1.1 after the implementation of eAG was better than those of other zones, the proportions of patients achieving therapeutic targets and the overall medians of HbA1c and LDL-c in each RHA zones were analyzed.

The Kruskal-Wallis statistic was conducted to compare the medians and inter quartile ranges of HbA1c and LDL-c from different zones from 2010 to 2014. Zone 1.1 was statistically different (*p* \< 0.05) comparing with Zones 3, Zone 4, Zone 6 and Zone 7 on HbA1c; Zone 1.1 was statistically different (*p* \< 0.05) comparing with Zones 2, Zone 3, and Zone 6 on LDL-C. Overall, the glycemic control and blood lipid control in pediatric diabetes patients in Zone 1.1 was at an intermediate level in all 8 zones.
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Supplementary material1. Pediatric raw data for HbA1c and LDL-c.Image, application 1
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